Protagenic Therapeutics, Inc.\new Proceeds from Issuance of Convertible Preferred Stock
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Issuance of Convertible Preferred Stock of $4.26 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-04-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2018-04-02
- Protagenic Therapeutics, Inc.\new proceeds from issuance of convertible preferred stock for fiscal 2016 was $4.26M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|
| 2016-12-31 | $4.26M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |